References
Saso R, Marsh J, Cevreska L, Szer J, Gale RP, Rowlings PA et al. Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. Br J Haematol 1999; 104: 392–396.
Woodard P, Wang W, Pitts N, Benaim E, Horwitz E, Cunningham J et al. Successful unrelated donor bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Bone Marrow Transplant 2001; 27: 589–592.
Flotho C, Strahm B, Kontny U, Duffner U, Peters AM, Dupuis W et al. Stem cell transplantation for paroxysmal nocturnal haemoglobinuria in childhood. Br J Haematol 2002; 118: 124–127.
Lee JL, Lee JH, Lee JH, Choi SJ, Kim S, Seol M et al. Allogeneic hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria. Eur J Haematol 2003; 71: 114–118.
Hegenbart U, Niederwieser D, Forman S, Holler E, Leiblein S, Johnston L et al. Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria. Biol Blood Marrow Transplant 2003; 9: 689–697.
Jochen C, Blau W, Volin L, Ruutu T, Wandt H, Schaefer-Eckart K et al. Allogeneic haematopoietic stem cell transplantation after treosulfan/fludarabine conditioning in high-risk patients with hematologic malignancies. Dose escalation of treosulfan. Blood 2003; 102: 467a (abstract 1704).
Grosskreutz C, Ross V, Scigliano E, Fruchtman S, Isola L . Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation. Biol Blood Marrow Transplant 2003; 9: 453–459.
Takahashi Y, McCoy JP Jr, Carvallo C, Rivera C, Igarashi T, Srinivasan R et al. In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation. Blood 2004; 103: 1383–1390.
Chakrabarti S, Takahashi Y, Srinivasan R, Espinoza I, Igarashi T, Suffredini D et al. Durable engraftment and long-term survival following fludarabine-based nonmyeloablative hematopoietic cell transplantation (HCT) in patients with ATG-refractory severe aplastic anemia (SAA) and other nonmalignant hematological disorders. Blood 2004; 104: 252.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Markiewicz, M., Wojciechowska, M., Wyleżoł, I. et al. Unrelated donor bone marrow transplantation with treosulfan-based myeloablative conditioning for paroxysmal nocturnal hemoglobinuria- successful treatment despite multiple transplant-related risk factors for hemolysis including major Kidd group incompatibility. Bone Marrow Transplant 37, 231–232 (2006). https://doi.org/10.1038/sj.bmt.1705210
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705210
- Springer Nature Limited
This article is cited by
-
Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT
Bone Marrow Transplantation (2008)
-
Preclinical studies of treosulfan demonstrate potent activity in Ewing’s sarcoma
Cancer Chemotherapy and Pharmacology (2008)